BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2299634)

  • 1. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
    Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
    J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
    Springer CJ; Niculescu-Duvaz I; Pedley RB
    J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
    J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
    J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds.
    Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG
    Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
    Capucha V; Mendes E; Francisco AP; Perry MJ
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
    Marais R; Spooner RA; Light Y; Martin J; Springer CJ
    Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
    Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ
    Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitors of carboxypeptidase G2 (CPG2): potential use in antibody-directed enzyme prodrug therapy.
    Khan TH; Eno-Amooquaye EA; Searle F; Browne PJ; Osborn HM; Burke PJ
    J Med Chem; 1999 Mar; 42(6):951-6. PubMed ID: 10090777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19F magnetic resonance spectroscopy.
    Mancini L; Davies L; Friedlos F; Falck-Miniotis M; Dzik-Jurasz AS; Springer CJ; Leach MO; Payne GS
    NMR Biomed; 2009 Jun; 22(5):561-6. PubMed ID: 19259950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.